{"nctId":"NCT02579161","briefTitle":"Trial of Randomized Antibiotic Administration in Percutaneous Nephrolithotomy","startDateStruct":{"date":"2014-09"},"conditions":["Kidney Stones"],"count":98,"armGroups":[{"label":"Antibiotics for a 24 hour period","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cephalosporins","Drug: Fluoroquinolones","Drug: Clindamycin","Drug: Ampicillin/Gentamicin"]},{"label":"Continued antibiotics","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: cephalosporins","Drug: Fluoroquinolones","Drug: Clindamycin","Drug: Ampicillin/Gentamicin"]}],"interventions":[{"name":"cephalosporins","otherNames":["ancef"]},{"name":"Fluoroquinolones","otherNames":["ciprofloxacin"]},{"name":"Clindamycin","otherNames":["Lincosamides"]},{"name":"Ampicillin/Gentamicin","otherNames":["Penicillinase-sensitive penicillin\\Aminoglycoside"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients \\>18 years old\n* Negative urine culture within 1 month prior to procedure\n* Renal Calculi which would optimally require PCNL for treatment.\n\nExclusion Criteria:\n\n* Patients \\<18 years old.\n* Patients who are not able to give consent for study\n* Patients currently on antibiotics immediately prior to the procedure\n* Previous history of sepsis or SIRS from stone manipulations\n* Foley catheter in place for greater than 1 week duration\n* Patients under going planned, multi-staged procedures\n* Immunosuppressed patients","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Infectious Complications","description":"Compare the rate of infectious complications following a single-dose of peri-operative protocol (antibiotics for 24 hours as recommended by the American Urological Association Guidelines) with a short-course protocol (antibiotics continued until any external catheters such as nephrostomy tubes are removed) following percutaneous nephrolithotomy. Complication rate differences, primarily infectious complications such as fever, sepsis, systemic inflammatory response.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Length of Stay (Days)","description":"Length of Hospital Stay After Surgery (days)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":"0.8"},{"groupId":"OG001","value":"1.5","spread":"1.9"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Associated Clavien Grade of Adverse Event","description":"Overall complication rates are reported based on Clavien-Dindo scale. The numbers reported are recorded Clavien complications. There is only one Clavien complication per patient as such a recorded number indicates one complication of this classification and also one patient with this complication. For example, if a Clavien III is recorded, it is indicating that one patient in that study group had one Clavien III complication.\n\nGrade I are any deviation from the normal post-operative course not requiring surgical, endoscopic or radiological intervention.\n\nGrade II complications require drug treatments other than those allowed for Grade I complications; Grade III complications require surgical, endoscopic or radiological intervention either IIIa, not under general anesthesia or IIIb, under general anesthesia. Grade IV are Life-threatening complications. Grade V are most severe and result in death of the patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":49},"commonTop":["fevers post operative","Post-operative embolization","Post operative urinary retention","Post operative pain","Post operative anemia requiring transfusion"]}}}